drugset / Trial / NCT03790852
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg
Timeline
- Start
- 2018-12-26
- Primary completion
- 2021-06-02
- Completion
- 2022-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tarcocimab tedromer | Protein / enzyme biologic | 2.5 mg | Intravitreal |
| Subject | Tarcocimab tedromer | Protein / enzyme biologic | 5 mg | Intravitreal |